MARKET

ARCT

ARCT

Arcturus Therape
NASDAQ
24.87
+0.93
+3.88%
After Hours: 24.74 -0.13 -0.52% 19:05 12/01 EST
OPEN
23.54
PREV CLOSE
23.94
HIGH
25.25
LOW
23.02
VOLUME
304.33K
TURNOVER
0
52 WEEK HIGH
37.75
52 WEEK LOW
14.21
MARKET CAP
664.61M
P/E (TTM)
7.51
1D
5D
1M
3M
1Y
5Y
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
NASDAQ · 1d ago
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
NASDAQ · 1d ago
Buy Rating for Arcturus Therapeutics: ARCT-154’s Global Regulatory Success and Market Potential
TipRanks · 3d ago
Arcturus, CSL win approval for world’s first self-amplifying mRNA vaccine in Japan
Healthcare arcturus, csl win approval for world’s first self-amplifying mrna vaccine in japan. Japan's ministry of health approves arct-154 covid-19 vaccine. Arcturus therapeutics and partner csl say it's the world's first regulatory clearance of a self-amplifying mrna.
Seeking Alpha · 3d ago
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
NASDAQ · 3d ago
HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Benzinga · 4d ago
Ed Arce Recommends ‘Buy’ on Arcturus Therapeutics Highlighting Orphan Drug Designation and Promising Cystic Fibrosis Treatment
Analyst ed arce from h.c. Wainwright remains neutral on the stock and has a $51.00 price target for arcturus therapeutics. Fda's orphan drug designation for cystic fibrosis treatment candidate arct-032 is cited as a positive factor.
TipRanks · 4d ago
Health Care Sector Update for 11/27/2023: ANVS, ABEO, ARCT
NASDAQ · 4d ago
More
About ARCT
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Webull offers Arcturus Therapeutics Holdings Inc stock information, including NASDAQ: ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.